Prosafe SE: Notice of Change to financial calendar
Due to a change in the timing of the Board meeting, the Q1 2020 results will be published on 26 May 2020 at about 01.30 p.m. CEST, which is one day earlier than originally announced. The Q1 2020 report and the Q1 2020 presentation will be published on www.newsweb.no and on Prosafe’s website www.prosafe.com
Jesper Kragh Andresen, CEO and Stig H. Christiansen, Deputy CEO & CFO will on 27 May 2020 at 10:00 a.m. CEST host an audio webcast. The webcast can be followed at www.prosafe.com
It will be possible to ask questions during the presentation by using the Q&A tool embedded in the audio webcast. A replay of the audio webcast will be made available at www.prosafe.com shortly after.
Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com
Stavanger, 25 May 2020
Prosafe SE
For further information, please contact:
Jesper K. Andresen, CEO
Phone: +47 51 65 24 30 / +47 907 65 155
Stig Harry Christiansen, Deputy CEO and CFO
Phone: +47 51 64 25 17 / +47 478 07 813
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Planlagt suspension i Kapitalforeningen BLS Invest23.4.2024 11:51:54 CEST | pressemeddelelse
Det skal oplyses, at der grundet lokale børslukkedage i underliggende markeder vil være suspension af nedenstående afdelinger onsdag d. 1 maj 2024. Fund nameISINOrder book codeGlobale Aktier KLDK0060189041BLKGAGlobale Aktier Akk.DK0060560167BLIGAA Eventuelle spørgsmål vedrørende denne meddelelse kan rettes til npa.pm@nykredit eller Christian Rye Holm, CRH@nykredit.dk. Med venlig hilsen Nykredit Portefølje Administration A/S Tage Fabrin-Brasted
Resolutions at the Annual General Meeting in HMS Networks23.4.2024 11:50:00 CEST | Press release
HMS Networks AB (publ) held its Annual General Meeting on April 23, 2024. The Meeting resolved in favour of all matters in accordance with the proposals of the Board of Directors and the Nomination Committee. The main contents of the most important resolutions are described below. ALLOCATION OF EARNINGS The Annual General Meeting resolved to approve the Board's proposed dividend of SEK 4.40 per share. The record date for the dividend was set to be April 25, 2024. The dividend is expected to be distributed by Euroclear Sweden on April 30, 2024. ADOPTION OF THE INCOME STATEMENT AND BALANCE SHEET AND DISCHARGE FROM LIABILITY The Annual General Meeting resolved to adopt the income statement and balance sheet for HMS Networks AB and the group as presented by the Board. The Board and the CEO were discharged from liability for the 2023 financial year. ELECTION OF BOARD MEMBERS AND AUDITORS AND DETERMINATION OF FEES The Annual General Meeting resolved in accordance with the Nominating Committe
Beslut vid årsstämman i HMS Networks23.4.2024 11:50:00 CEST | Pressemelding
HMS Networks AB (publ) har den 23 april 2024 hållit årsstämma. I samtliga ärenden beslutade stämman i enlighet med styrelsens och valberedningens förslag. I det följande redogörs för de viktigaste beslutens huvudsakliga innehåll. VINSTDISPOSITION Årsstämman beslutade att bifalla styrelsens förslag om utdelning med 4,40 kr per aktie. Som avstämningsdag för utdelning fastslogs den 25 april 2024. Utdelning beräknas därmed att utsändas genom Euroclear Swedens försorg den 30 april 2024. FASTSTÄLLANDE AV RESULTAT- OCH BALANSRÄKNING OCH ANSVARSFRIHET Årsstämman beslutade att fastställa av styrelsen framlagd resultat- och balansräkning för HMS Networks AB och koncernen. Styrelsen och bolagets verkställande direktör beviljades ansvarsfrihet för räkenskapsåret 2023. VAL AV STYRELSE OCH REVISOR SAMT BESLUT OM ARVODEN Årsstämman beslutade i enlighet med valberedningens förslag, nämligen att sex (6) ordinarie styrelseledamöter väljs utan några styrelsesuppleanter,att ett (1) registrerat revisionsbo
Planlagt suspension i Investeringsforeningen Nykredit Invest Balance23.4.2024 11:49:22 CEST | pressemeddelelse
Det skal oplyses, at der grundet lokale børslukkedage i underliggende markeder vil være suspension af nedenstående afdelinger onsdag d. 1 maj 2024. Fund nameISINOrder book codeBæredygtig Defensiv KLDK0061671013NBIBDKLBæredygtig Moderat KLDK0061671286NBIBMKLBæredygtig Offensiv KLDK0061671369NBIBOKLDefensiv KLDK0016188733NBIDEKLModerat KLDK0016188816NBIMOKLOffensiv KLDK0060441749NBIOFKL Eventuelle spørgsmål vedrørende denne meddelelse kan rettes til npa.pm@nykredit eller Christian Rye Holm, CRH@nykredit.dk. Med venlig hilsen Nykredit Portefølje Administration A/S Tage Fabrin-Brasted
Major shareholder announcement - Pharma Equity Group A/S23.4.2024 11:45:20 CEST | Press release
Major shareholder announcement - Pharma Equity Group A/S 23 April 2024 Company Announcement no. 14 Pharma Equity Group A/S has, in accordance with section 38 of the Capital Markets Act, received major shareholder notification, that DMZ Holding ApS has acquired shares in Pharma Equity Group A/S. As a result, DMZ Holding ApS has increased their ownership stake to over 5% in Pharma Equity Group A/S. For further information, please contact: Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022 2114 Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: +45 2622 7222 About Pharma Equity Group A/S Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects. The compan